25.9 C
New York
Tuesday, June 9, 2026

Tag: 18

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, June 7, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Indonesian Firms Confront 18.9% Cost Surge as APAC Supply Chains Pivot to AI and Predictability

JAKARTA, Indonesia, June 7, 2026 /PRNewswire/ -- Indonesian retail and logistics sectors are aggressively restructuring supply chains following a major report revealing an 18.9%...

Thai Enterprises Face 18.9% Delivery Cost Surge as APAC Supply Chains Shift to AI and Reliability

BANGKOK, June 7, 2026 /PRNewswire/ -- Thailand's retail and logistics sectors are urgently overhauling supply chains following a major report revealing an 18.9% surge...

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Badger Meter, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BMI

NEW YORK, June 06, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Badger Meter, Inc. (NYSE: BMI) between April 18, 2024 and April 16, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026.

Real-World Evidence of Eversense 365 Presented at ADA Demonstrating Strong Performance and Patient Impact in Both Open and Closed Loop Systems

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM’s differentiated approach and high performance 

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags18